HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plant-Based Smoking Cessation Alternative Cytisine ‘Likely’ To Help Quitters

Executive Summary

“Moderate-certainty evidence” shows that low-cost smoking cessation therapy cytisine “probably” helps more people to quit smoking than a placebo and “low-certainty evidence” suggests that the natural alternative may also help more people to quit than using a nicotine replacement monotherapy, finds a recently published Cochrane Review.

You may also be interested in...

Why Did Germany Reject OTC Switch Of Low-Cost Smoking Cessation Drug Cytisine?

At its first meeting of 2023, Germany's switch committee voted against switching to OTC status low-cost smoking cessation drug cytisine. Complex treatment guidelines and concerns about side effects were among the considerations leading to this decision, the recently published minutes show.

EFSA Considering New CBD Toxicity Data While Clock-Stop Causes Industry ‘Economic Harm’

The European Food Safety Authority is evaluating new reproductive and developmental toxicity data published since it paused CBD novel food applications last year due to safety concerns, according to food law consultancy, Legal Foods.

German OTC Launches: Bayer Adds Probiotics, Angelini Expands ThermaCare, And More

Two microbiome products added to Bayer's Iberogast line, a new drug-free pain-relieving ThermaCare knee brace from Angelini Pharma and an ashwagandha-powered sleep aid extension to Oyono from Klosterfrau feature in this German marketing update. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts